Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873076 | 1.00 | NR1I2 (0.46) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL7614200 | 1.00 | NR1I2 (0.46) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL31175819 | 1.00 | NR1I2 (0.46) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL1331317 | 1.00 | NR1I2 (0.46) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL8509029 | 1.00 | NR1I2 (0.46) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL3072581 | 1.00 | NR1I2 (0.46) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL4181323 | 1.00 | NR1I2 (0.46) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL5423814 | 0.98 | SIGMAR1 (0.44) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| Fluoride SCHEMBL9717306 | 0.96 | SIGMAR1 (0.43) | NR1I2HTR2ACSNK1ESIGMAR1NAAA | |
| SCHEMBL23849703 | 0.96 | NR1I2 (0.49) | NR1I2HTR2ACSNK1ESIGMAR1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-113167695-A | Device for collecting volatile organic compounds | 法国由内政部代表 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020021969-A1 | COMPOSITION, CURED PRODUCT, OPTICAL FILTER, AND PRODUCTION METHOD FOR CURED PRODUCT | 株式会社ADEKA | 2020-01-30 | — | — | WO | disclosed |
| CN-107636024-A | Composition | 株式会社艾迪科 | 2018-01-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, NOD1 | NR1I2 57/4885HTR2A 2407/4885CSNK1E 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.